Saturday 17 October 2026
Export CLRB’s income statement to Excel — free account
Cellectar Biosciences, Inc.
CLRB Healthcare Biotechnology
In the quarter to June 2026, EPS grew 83.2% and free cash flow fell 17.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.14
0.05
−4.20%
Follow CLRB
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(417.71%) | (200.01%) | (395.20%) | (125.99%) | |
| (72.62%) | (107.74%) | (153.46%) | (88.70%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(202.60%) | (221.49%) | (440.33%) | (74.55%) | |
Free Cash Flow per Share |
(9.39) | (8.90) | (4.40) | (1.60) | |
Free Cash Flow |
(29.69) | (23.21) | (18.65) | (19.55) | |
Capital Expenditures |
— | (0.09) | (0.07) | (0.07) | |
| Other line items | |||||
Cash ROIC |
(142.13%) | (106.78%) | (159.65%) | (30.60%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
1.57 | 1.06 | 0.89 | 0.87 | |
Depreciation/Fixed assets |
0.39 | 0.39 | 0.14 | 0.09 | |
Capex/Depreciation |
0.00 | (0.41) | (1.49) | (2.60) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(9.39) | (8.86) | (4.38) | (1.59) | |
Capex per Share |
0.00 | (0.03) | (0.02) | (0.01) | |
Capex to Sales |
— | 0.00 | 0.00 | 0.00 |
Columns are period end dates